



Tolebrutinib for Secondary Progressive Multiple Sclerosis: Effectiveness and Value

Revised Questions for Deliberation and Voting: June 13th CTAF Public Meeting

These questions are intended for the deliberation of the CTAF voting body at the public meeting.

Patient Population for all questions: *Adults with non-relapsing secondary progressive multiple sclerosis.*

**Defined as pharmacological and non-pharmacological treatments to alleviate the symptoms of MS.*

Clinical Evidence

1. Is the current evidence adequate to demonstrate that the net health benefit of tolebrutinib is greater than that of best supportive care*?

Yes

No

Benefits Beyond Health and Special Ethical Priorities

To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements:

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

2. There is substantial unmet need despite currently available treatments.
3. This condition is of substantial relevance for people from a racial/ethnic group that has not been equitably served by the healthcare system.

To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements based on the relative effects of tolebrutinib versus best supportive care:

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

4. The treatment is likely to produce substantial improvement in caregivers' quality of life and/or ability to pursue their own education, work, and family life.
5. The treatment offers a substantial opportunity to improve access to effective treatment by means of its mechanism of action or method of delivery.

Long-Term Value for Money

6. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of tolebrutinib compared to best supportive care at assumed pricing?*
- a. High long-term value for money at assumed pricing
- b. Intermediate long-term value for money at assumed pricing
- c. Low long-term value for money at assumed pricing

**This vote will only be taken if a price becomes available for tolebrutinib.*